

Nos. 2024-1564, -1567

**UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT**

REGENERON PHARMACEUTICALS, INC.,

Appellant,

v.

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., SAMSUNG BIOEPIS CO., LTD.,

Appellees.

Appeals from the United States Patent and Trademark Office, Patent Trial and
Appeal Board in Nos. IPR2022-01225, IPR2023-00532, IPR2022-01226,
IPR2023-00533, and IPR2023-00566.

**APPELLANT REGENERON PHARMACEUTICALS, INC.’s MOTION
FOR VOLUNTARY DISMISSAL UNDER FED. R. APP. P. 42(B)(2)**

Pursuant to Federal Rule of Appellate Procedure 42(b), Appellant
Regeneron Pharmaceuticals, Inc. (“Regeneron”) hereby moves to voluntarily
dismiss the above-captioned appeals. On July 23, 2024, Regeneron contacted
counsel for Appellees to seek consent for a joint stipulation of voluntary dismissal
in which each side would bear its own costs. Counsel for Appellee Mylan
Pharmaceuticals, Inc. consented on July 25, and counsel for Appellee Celltrion,
Inc. consented on July 26.

Regeneron contacted counsel for Appellee Samsung Bioepis Co., Ltd. about
the joint stipulation of voluntary dismissal on July 23, July 26, July 29, July 31,

and August 2. In the last two communications, Regeneron indicated that it would file a motion to dismiss its appeal if it did not hear back from Samsung Bioepis regarding the joint stipulation of voluntary dismissal. To date, counsel for Samsung Bioepis has not responded to Regeneron's emails and phone call.

Because Regeneron does not wish to further pursue the above-captioned appeals, in which the opening brief is due on August 5, 2024, Regeneron respectfully requests that the Court dismiss the appeals pursuant to Federal Rule of Appellate Procedure 42(b).

Respectfully submitted,

/s/ Thomas G. Saunders

THOMAS G. SAUNDERS

WILMER CUTLER PICKERING

HALE AND DORR LLP

2100 Pennsylvania Avenue, NW

Washington, DC 20037

(202) 663-6000

*Counsel for Appellant Regeneron
Pharmaceuticals, Inc.*

August 5, 2024

CERTIFICATE OF INTEREST

Counsel for Appellant Regeneron Pharmaceuticals, Inc. certifies the following:

1. Represented Entities. Fed. Cir. R. 47.4(a)(1). Provide the full names of all entities represented by undersigned counsel in this case.

Regeneron Pharmaceuticals, Inc.

2. Real Party in Interest. Fed. Cir. R. 47.4(a)(2). Provide the full names of all real parties in interest for the entities. Do not list the real parties if they are the same as the entities.

None.

3. Parent Corporations and Stockholders. Fed. Cir. R. 47.4(a)(3). Provide the full names of all parent corporations for the entities and all publicly held companies that own 10% or more stock in the entities.

None.

4. Legal Representatives. List all law firms, partners, and associates that (a) appeared for the entities in the originating court or agency or (b) are expected to appear in this court for the entities. Do not include those who have already entered an appearance in this court. Fed. Cir. R. 47.4(a)(4).

ARNOLD & PORTER KAYE SCHOLER LLP: David Caine, Jeremy Cobb, David Denuyl, Alice Sin Yu Ho, Daniel L. Reisner, Matthew M. Wilk

MORRISON & FOERSTER LLP: Daralyn Durie

5. Related Cases. Other than the originating case(s) for this case, are there related or prior cases that meet the criteria under Fed. Cir. R. 47.5(a)?

Yes (file separate notice; see below) No N/A (amicus/movant)

If yes, concurrently file a separate Notice of Related Case Information that complies with Fed. Cir. R. 47.5(b). Please do not duplicate information. This separate Notice must only be filed with the first Certificate of Interest or, subsequently, if information changes during the pendency of the appeal. Fed. Cir. R. 47.5(b).

Already filed.

6. Organizational Victims and Bankruptcy Cases. Provide any information required under Fed. R. App. P. 26.1(b) (organizational victims in criminal cases) and 26.1(c) (bankruptcy case debtors and trustees). Fed. Cir. R. 47.4(a)(6).

None.

Dated: August 5, 2024

/s/ Thomas G. Saunders
THOMAS G. SAUNDERS
WILMER CUTLER PICKERING
HALE AND DORR LLP
2100 Pennsylvania Avenue, NW
Washington, DC 20037
(202) 663-6000

**CERTIFICATE OF COMPLIANCE WITH TYPE-VOLUME
LIMITATIONS**

The foregoing filing complies with the relevant type-volume limitation of the Federal Rules of Appellate Procedure and Federal Circuit Rules because:

1. The filing has been prepared using a proportionally spaced typeface and includes 184 words.
2. The brief has been prepared using Microsoft Word for Office 365 in 14-point Times New Roman font. As permitted by Fed. R. App. P. 32(g), the undersigned has relied upon the word count feature of this word processing system in preparing this certificate.

/s/ Thomas G. Saunders
THOMAS G. SAUNDERS
WILMER CUTLER PICKERING
HALE AND DORR LLP
2100 Pennsylvania Avenue, NW
Washington, DC 20037
(202) 663-6000

August 5, 2024